Aclaris Therapeutics (ACRS) Interest Expenses (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Interest Expenses of $14.7 million for Q1 2026, up 1878.57% year-over-year from $742000.0 in Q1 2025, and up 70.77% quarter-over-quarter from $8.6 million in Q4 2025.
Aclaris Therapeutics (ACRS) Interest Expenses (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Interest Expenses history runs 13 years deep, the most recent figure standing at $14.7 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 1878.57% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $14.7 million (up 1878.57% YoY), while the FY2025 annual figure was $197.1 million, down 12.15% from the prior year.
- Interest Expenses for Q1 2026 stood at $14.7 million, up from $8.6 million in the prior quarter.
- The five-year high for Interest Expenses was $195.1 million in Q4 2023, with the low at $81000.0 in Q3 2024.
- The 5-year median for Interest Expenses is $4.7 million (2023), against an average of $17.7 million.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses plunged 98.48% in 2024, then soared 2562.96% in 2025.
- Aclaris Therapeutics' Interest Expenses stood at $15.3 million in 2022, then surged by 1176.32% to $195.1 million in 2023, then slumped by 98.48% to $3.0 million in 2024, then surged by 189.66% to $8.6 million in 2025, then surged by 70.77% to $14.7 million in 2026.
- Business Quant data shows ACRS's Interest Expenses at $14.7 million in Q1 2026, $8.6 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 32.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.43 Mn |
| Jun 30, 2026 | 32.43 Mn |
| Mar 31, 2026 | 14.68 Mn |
| Mar 31, 2026 | 14.68 Mn |
| Dec 31, 2025 | 8.60 Mn |
| Dec 31, 2025 | 8.60 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Jun 30, 2025 | 506,000.00 |
| Jun 30, 2025 | 506,000.00 |
| Mar 31, 2025 | 742,000.00 |
| Mar 31, 2025 | 742,000.00 |
| Dec 31, 2024 | 2.97 Mn |
| Dec 31, 2024 | 2.97 Mn |
| Sep 30, 2024 | 81,000.00 |
| Sep 30, 2024 | 81,000.00 |
| Jun 30, 2024 | 479,000.00 |
| Jun 30, 2024 | 479,000.00 |
| Mar 31, 2024 | 487,000.00 |
| Mar 31, 2024 | 487,000.00 |